Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.
Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.
Researchers are assessing GC012F (AZD0120) in people with multiple myeloma that came back or keeps growing after treatment. In the first part of this study, researchers will find the best dose of GC012F to use in patients. In the second part of the study, they will assess this dose to treat advanced multiple myeloma.
Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.
Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.
Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
